We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-20.21%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$2.65B
AUM Growth
-$1.6B
Cap. Flow
-$640M
Cap. Flow %
-24.1%
Top 10 Hldgs %
99.61%
Holding
13
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
+$63.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$671M
2
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
+$32.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$1.84B 69.35%
12,886,743
-4,694,273
-27% -$671M
SANA icon
2
Sana Biotechnology
SANA
$885M
$220M 8.29%
34,239,018
– –
FHTX icon
3
Foghorn Therapeutics
FHTX
$285M
$172M 6.49%
12,674,120
– –
EVLO
4
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$106M 4.01%
2,521,366
+1,369,863
+119% +$63.5M
OMGA
5
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$98.4M 3.71%
25,902,269
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.67B
$77.1M 2.9%
2,619,968
– –
MCRB icon
7
Seres Therapeutics
MCRB
$48.1M
$49.3M 1.86%
718,940
– –
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
$38.3M 1.44%
754,711
– –
RUBY
9
DELISTED
Rubius Therapeutics, Inc
RUBY
$32.7M 1.23%
38,506,526
– –
SGTX
10
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$8.61M 0.32%
797,721
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$7.51M 0.28%
2,607,303
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.82M 0.11%
293,849
– –
KLDO
13
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
– –
-19,575,710
Closed -$32.3M

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q2 2022 Portfolio in Review

As of Q2 2022, Flagship Pioneering held 13 positions worth $2.65B, down 38% from $4.26B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering withdrew a net $640M in Q2 2022, closing 1 position and reducing 1 holding. Its most notable exit was Kaleido Biosciences, Inc. Common Stock, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Flagship Pioneering added an estimated $63.5M to Evelo Biosciences, Inc. Common Stock.

  • Flagship Pioneering added most to Evelo Biosciences, Inc. Common Stock in Q2 2022, an estimated $63.5M increase.
  • Flagship Pioneering's biggest Q2 2022 reduction was Moderna, cutting an estimated $671M.
  • Flagship Pioneering fully exited Kaleido Biosciences, Inc. Common Stock in Q2 2022, selling an estimated $32.3M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $2.65B portfolio in Q2 2022.
  • Flagship Pioneering opened 0 new positions and closed 1 in Q2 2022.
  • Flagship Pioneering's portfolio value fell 38% quarter-over-quarter to $2.65B.

Based on Flagship Pioneering's 13F filing for Q2 2022, filed 15 Aug 2022.